Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tong Ren Tang Technologies Co ( (HK:1666) ) just unveiled an update.
Tong Ren Tang Technologies Co. Ltd. announced that shareholders approved all resolutions at an extraordinary general meeting held in Beijing on 30 December 2025. Investors endorsed the renewal of the Distribution Framework Agreement and the Master Procurement Agreement with China Beijing Tong Ren Tang Group Co., Ltd. for the period from 1 January 2026 to 31 December 2028, ensuring the continuation of key connected transactions that underpin the group’s sales and supply-chain arrangements. The meeting also approved the appointment of Ms. Du Xin as a non-executive director of the ninth session of the board and her related remuneration package, reinforcing the company’s governance structure as it enters a new three-year operating cycle under refreshed intra-group commercial frameworks.
The most recent analyst rating on (HK:1666) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Tong Ren Tang Technologies Co stock, see the HK:1666 Stock Forecast page.
More about Tong Ren Tang Technologies Co
Tong Ren Tang Technologies Co. Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong. It forms part of the Tong Ren Tang group, a long-established Chinese pharmaceutical and health products conglomerate, focusing on traditional Chinese medicine manufacturing, distribution and related healthcare services in domestic and overseas markets.
Average Trading Volume: 1,033,606
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.71B
See more insights into 1666 stock on TipRanks’ Stock Analysis page.